Intranasal COVID-19 vaccine

The experimental DelNS1-2019-nCoV-RBD-OPT1 COVID-19 vaccine, based on a replicating viral vector (influenza
virus), developed by the University of Hong Kong, Xiamen University, and Beijing Wantai Biological Pharmacy, is
currently under a phase II clinical trial.

This intranasally administered vaccine has the potential advantage of preventing COVID-19 infection by stimulating
mucosal response in the vaccinated population. The development is supported by the Coalition for Epidemic
Preparedness Innovations (CEPI), which is collaborating on vaccine research and development for the COVAX
Mechanism. More information about this study can be found at: http://www.chictr.org.cn/enIndex.aspx.

Source: CEPI and University of Hong Kong expand partnership to develop intranasal COVID-19 vaccine candidate.
CEPI NEWS. 18 March 2021